MAP2K1 and melanoma: During a median follow-up of 32 months (IQR 15–46 months), 15 melanoma patients (28.8%), all with pT2a–pT4b tumours, developed metastatic melanoma: nine with Class I, three with Class II, and three with Class III MAP2K1 mutations (Table 1 and Fig. 2).